New cancer drug LB4330 tested in early trial
Disease control
Terminated
This early-phase trial tested a new drug called LB4330 in people with advanced solid tumors that had stopped responding to standard treatments. LB4330 is designed to help the immune system attack cancer cells. The study aimed to find a safe dose and check for side effects, but it…
Phase: PHASE1 • Sponsor: L & L Bio Co., Ltd., Ningbo, China • Aim: Disease control
Last updated Jun 26, 2026 16:51 UTC